JP2009528985A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528985A5
JP2009528985A5 JP2008552918A JP2008552918A JP2009528985A5 JP 2009528985 A5 JP2009528985 A5 JP 2009528985A5 JP 2008552918 A JP2008552918 A JP 2008552918A JP 2008552918 A JP2008552918 A JP 2008552918A JP 2009528985 A5 JP2009528985 A5 JP 2009528985A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
trkb
agonist
trkb agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008552918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2007/000254 external-priority patent/WO2007088476A1/en
Publication of JP2009528985A publication Critical patent/JP2009528985A/ja
Publication of JP2009528985A5 publication Critical patent/JP2009528985A5/ja
Withdrawn legal-status Critical Current

Links

JP2008552918A 2006-02-02 2007-02-01 trkBアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法 Withdrawn JP2009528985A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76541006P 2006-02-02 2006-02-02
PCT/IB2007/000254 WO2007088476A1 (en) 2006-02-02 2007-02-01 Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist

Publications (2)

Publication Number Publication Date
JP2009528985A JP2009528985A (ja) 2009-08-13
JP2009528985A5 true JP2009528985A5 (enExample) 2009-10-15

Family

ID=38093467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552918A Withdrawn JP2009528985A (ja) 2006-02-02 2007-02-01 trkBアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法

Country Status (17)

Country Link
US (2) US20070248611A1 (enExample)
EP (1) EP1988923A1 (enExample)
JP (1) JP2009528985A (enExample)
KR (1) KR20080091838A (enExample)
CN (1) CN101400367A (enExample)
AR (1) AR059304A1 (enExample)
AU (1) AU2007210862A1 (enExample)
BR (1) BRPI0707482A2 (enExample)
CA (1) CA2637826A1 (enExample)
DO (1) DOP2007000021A (enExample)
IL (1) IL193069A0 (enExample)
NL (1) NL2000464C2 (enExample)
PE (1) PE20071364A1 (enExample)
RU (1) RU2008131939A (enExample)
TW (1) TW200808352A (enExample)
UY (1) UY30128A1 (enExample)
WO (1) WO2007088476A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082401A1 (en) * 2004-02-20 2005-09-09 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
MX2009004881A (es) * 2006-11-09 2009-05-21 Irm Llc Anticuerpos agonistas de trkb y usos de los mismos.
US20100086997A1 (en) * 2006-12-20 2010-04-08 Rinat Enuroscience Corp TrkB Agonists for Treating Autoimmune Disorders
JP2011501760A (ja) * 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのtrkb抗体の使用
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
FR2942409B1 (fr) * 2009-02-20 2013-07-26 Natacha Voillot Composition pharmaceutique pour la prevention des avortements a repetition.
GB2491106A (en) * 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
CA3005491A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
MY203247A (en) * 2017-11-30 2024-06-19 Regeneron Pharma Anti-trkb monoclonal antibodies and methods of use

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5364768A (en) * 1987-07-07 1994-11-15 Farmitalia Carlo Erba S.R.L. Process for the preparation of penems
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
ATE174514T1 (de) * 1989-01-23 1999-01-15 Chiron Corp Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
US5644034A (en) * 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1992005254A1 (en) * 1990-09-25 1992-04-02 Genentech, Inc. Novel neurothrophic factor
US6566091B1 (en) 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US5702906A (en) * 1990-09-25 1997-12-30 Genentech, Inc. Antibodies to neurotrophic factor-4 (NT-4)
ATE193600T1 (de) * 1990-11-20 2000-06-15 Dade Behring Marburg Gmbh Verfahren zur stabilisierung von enzym-konjugaten
US20030134815A1 (en) * 1991-08-20 2003-07-17 The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU674881B2 (en) * 1992-09-07 1997-01-16 Biotechnology And Biological Sciences Research Council, The Growth hormone potentiating molecules
AU4920893A (en) * 1992-09-14 1994-04-12 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
US5759573A (en) * 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
JP2534968B2 (ja) * 1993-05-27 1996-09-18 チッソ株式会社 フラビン還元酵素遺伝子
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US20030191061A1 (en) * 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
WO1995031183A1 (en) * 1994-05-16 1995-11-23 Washington University Cell membrane fusion composition and method
MX9606598A (es) * 1994-06-24 1997-05-31 Behringwerke Ag Procedimiento para la estabilizacion de moleculas, o partes de moleculas, sensibles a la hidrolisis.
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
EP0942930B1 (en) 1996-11-15 2007-08-29 Genentech, Inc. Purification of neurotrophins
WO1998032458A1 (en) * 1997-01-23 1998-07-30 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
BR9811923A (pt) * 1997-08-29 2000-08-15 Vertex Pharma Compostos possuindo atividade neuronal
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
ATE405636T1 (de) * 1999-06-16 2008-09-15 Boston Biomedical Res Inst Immunologische kontrolle des beta-amyloid gehaltes in vivo
JP2004510684A (ja) * 1999-07-06 2004-04-08 バーテックス ファーマシューティカルズ インコーポレイテッド 神経学的疾患の治療のためのアゾアミノ酸誘導体
EP1226139A2 (en) * 1999-07-06 2002-07-31 Vertex Pharmaceuticals Incorporated Cyclized amide derivatives for treating or preventing neuronal damage
EP1200440A1 (en) * 1999-07-06 2002-05-02 Vertex Pharmaceuticals Incorporated Quinuclidine derivatives for treatment of neurological disorders
WO2001002376A1 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Amino-alkyl derivatives
JP2003503482A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 環化アミノ酸誘導体
JP2003505508A (ja) * 1999-07-30 2003-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非環式又は環式アミド誘導体
PT1223966E (pt) * 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
US20030022840A1 (en) * 2000-02-18 2003-01-30 Michiko Kishino Drugs for ameliorating impaired glucose tolerance
US20030036512A1 (en) * 2000-03-06 2003-02-20 Tsutomu Nakagawa Leptin-resistance amerliorating agents
PL208113B1 (pl) 2000-06-22 2011-03-31 Genentech Inc Agonistyczne przeciwciało monoklonalne anty-trkC, mysie agonistyczne przeciwciało monoklonalne, ludzkie agonistyczne przeciwciało monoklonalne, wyizolowana cząsteczka kwasu nukleinowego kodująca mysie agonistyczne przeciwciało monoklonalne, wyizolowana cząsteczka kwasu nukleinowego kodująca ludzkie przeciwciało anty-trkC, cząsteczka kwasu nukleinowego, linia komórek gospodarza, linia komórek hybrydomy, przeciwciało wytwarzane przez tę linię komórek hybrydomy, wyizolowana cząsteczka kwasu nukleinowego i wektor zawierający tę cząsteczkę kwasu nukleinowego, przeciwciało, polipeptyd, kompozycja
US7060429B2 (en) * 2001-02-22 2006-06-13 University Of Maryland, Baltimore Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
WO2002102381A1 (en) * 2001-06-14 2002-12-27 Vertex Pharmaceuticals Incorporated Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
WO2005082401A1 (en) * 2004-02-20 2005-09-09 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5

Similar Documents

Publication Publication Date Title
JP2009528985A5 (enExample)
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
JP2009522296A5 (enExample)
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
EP2583978A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
Lee et al. Comparison of ramosetron plus dexamethasone with ramosetron alone on postoperative nausea, vomiting, shivering and pain after thyroid surgery
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
JP2009525343A5 (enExample)
JP2007504174A5 (enExample)
JP2016147915A5 (enExample)
RU2008131939A (ru) Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
JP2007523135A5 (enExample)
PH12012502202A1 (en) Susbtituted heterocyclyl benzyl pyrazoles and use thereof
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2015070234A3 (en) Neuroprotective compounds and use thereof
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
CL2007002196A1 (es) Compuestos heterociclicos nitrogenados, moduladores de la actividad del receptor de quimioquina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, obesidad, sindrome metabolico y dolor.
JP2012528856A5 (enExample)
DK2802319T3 (da) Fastdosiskombinationsterapi for parkinsons sygdom
JP2007119497A5 (enExample)
JP2005530735A5 (enExample)
CL2007003484A1 (es) Composicion farmaceutica que comprende valsartan y un tensoactivo, un componente lipofilico y un componente hidrofilico; procedimiento de preparacion; y uso en el tratamiento de la insuficiencia cardiaca, angina, infarto de miocardio, arterioescleros